65,437 trials
Type 2 Diabetes Mellitus
Primary: Participants With Any Clinical Adverse Experience — 51.9; 61.1 percentage of of participants
Chronic Obstructive Pulmonary Disease · COPD
Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85
Staphylococcal Infection
Primary: Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level — 4.4; 0.9 Ratio
Leukaemia, Lymphocytic, Chronic
Primary: Number of Participants (Par.) Classified as Responders (Rs) and Non-responders (NRs) for Objective Response in Accordance With the National Cancer Institute Working…
Metastatic Melanoma
Primary: Recommended Phase II Dose — 70; 800 mg
Osteoporosis
Primary: Percentage of Participants With Non-Vertebral Fragility Fractures — 1.42; 0.91; 0.70; 0.81 Percentage of participants — p=0.0177
Breast Cancer
Primary: Number of Participants With Complete Pathologic Response Rate to Pre-operative Treatment in Arm A (Docetaxel for 4 Cycles Followed by Capecitabine for 4 Cycles) or Arm B…
General Anesthesia · Intravenous Anesthesia
Primary: Percentage of Participants Reporting Pain With Injection of Propofol — 29; 57; 41; 46 percentage of patients reporting pain
Growth Hormone Disorder · Growth Hormone Deficiency in Children · Foetal Growth Problem
Primary: The Relative Ease of Use of NordiFlex® Compared to the Device Previously Used — 6.89 units on a scale
Catheter Infections · Spinal Catheter (Epidural) (Subdural); Complications, Infection or Inflammation
Primary: Catheter Tip Colonization — 2; 3 participants
Pterygium
Primary: The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. — 5.75 area in millimeters squared…
Heart Arrest
Primary: Rate of ROSC During the Prehospital Resuscitation — 361; 345 Participants — p=0.96
Coronary Atherosclerosis
Primary: Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV) — -1.22; -0.99 Percent change
Myelodysplastic Syndromes
Primary: Number of Participants With Marrow Complete Remission (CR) — 3 participants
Tobacco Dependence · Smoking Cessation
Primary: Rating of Urges to Smoke 24 Hours and One Week After the Target Quit Date Assessed by Mood and Physical Symptoms Scale — 2.47; 2.88 units on a scale — p=0.14